CD274 and intrahepatic cholangiocarcinoma: This retrospective study was conducted at Ruijin Hospital, Shanghai, China, and included patients with primary liver cancer, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), who received anti-PD-1/PD-L1 treatment between July 2019 and July 2021.